While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up?
Since the dawn of immuno-oncology broke with checkpoint inhibitors, innovative therapies like Keytruda and Rituxan from big pharma have taken the world by storm. European biotech’s pipeline is full of potential successors born from T-Cell Receptors (TCR), monoclonal antibodies (mAbs), T-Cell Fragments, Chimeric Antigen Receptor-modified T cells (CAR-T) and tumor-infiltrating lymphocytes (TIL).
Medigene is leading the TCR race, with Immunocore not far behind with its fragments. Celyad and Cellectis are fierce rivals in CAR-T therapy and in a dead heat. The antibody pipeline is jam-packed with biotechs at every stage of development. TILs are a lesser-known area of immuno-oncology, but Cellular Therapeutics has developed one of the most advanced programs in the field.
Check out how far companies and their therapies have come in immuno-oncology!
Major thanks to our guides and Accellerate Partners for their input! Please note that this infographic is not meant to be comprehensive.
Note: TILT is sponsoring a trial in which the TIL is bolstered with an oncolytic virus.
Justine Braguy is pursuing a PhD at the Heinrich Heine Universität in Düsseldorf and KAUST in Saudi Arabia after obtaining a Masters in Biotechnology at Ecole Supérieure de Biotechnologie de Strasbourg (ESBS). In her spare time, she creates colourful infographics like this one! Check out her other work for us here.
Infographic by Justine Braguy ; Image from Agor2012/shutterstock.com